Hepatology

Filter

Efruxifermin Improves Fibrosis in Long-Term MASH Study

June 2025

In this double-blind, placebo-controlled trial, 181 participants were randomised to receive weekly injections of either 28 mg or 50 mg of efruxifermin or a placebo.

Efruxifermin Improves Fibrosis in Long-Term MASH Study

In this double-blind, placebo-controlled trial, 181 participants were randomised to receive weekly injections of either 28 mg or 50 mg of efruxifermin or a placebo.

National Study Reveals Gaps in Paediatric Hepatitis C Treatment

These figures indicate a substantial drop-off following diagnosis, undermining efforts to eliminate HCV in paediatric populations.

AI Tool Accurately Predicts Liver Graft Injury Causes

The model analyses demographic information, lab results, and other clinical data to predict the cause of graft injury across six possible conditions.

Extracellular Volume Fraction Predicts Cirrhosis Severity Accurately

This new study highlights the growing role of extracellular volume measurement using spectral CT, which quantifies the proportion of extracellular matrix.

Weight Loss Alters Liver Fatty Acid Metabolism Pathways

The findings support the concept that excessive lipogenesis, rather than just fat delivery from other sources, is central to MASLD development.

Pemafibrate Reduces Liver Fat and Heart Disease Risk

A study has revealed that pemafibrate is more effective than omega-3 fatty acid ethyl in reducing fatty liver index.

Dual Diabetes Drug Regimen Shows Promise for MASLD

Discover a study that suggests that dual therapy could offer a safer and more effective approach to treating MASLD.

Bariatric Surgery Alters Fibrinogen Profiles in MASLD

A recent study investigated how different naturally occurring fibrinogen variants relate to obesity, MASLD, and liver fibrosis severity.

Loading posts...

1 2 3 … 28 Next »